Fibrinogen Level and Bleeding Risk During Catheter-Directed Thrombolysis Using Tissue Plasminogen Activator. Vasc Endovascular Surg 2015 Oct;49(7):175-9
Date
10/16/2015Pubmed ID
26462979DOI
10.1177/1538574415611234Scopus ID
2-s2.0-84947269357 (requires institutional sign-in at Scopus site) 21 CitationsAbstract
PURPOSE: The purpose of this study was to determine whether low fibrinogen levels (fibrinogen level <1.5 g/L) during catheter-directed thrombolysis are associated with an increased bleeding risk.
METHODS: A retrospective review was performed on patients undergoing extremity arterial or venous thrombolysis between 2005 and 2013.
RESULTS: Patients in the low fibrinogen group were younger (P = .006) and had a higher number of venous occlusive events (P = .004). The low fibrinogen group received a larger dose of tissue plasminogen activator (tPA; P = .009) and had a longer duration of thrombolysis (P = .010). The rates of major bleeding were not significantly different (P = .139). Univariate analysis showed that larger total dose and longer duration of tPA infusion were associated with increased bleeding complications (P < .01 and P = .03).
CONCLUSION: A fibrinogen level <1.5 g/L during thrombolysis was not associated with an increased bleeding risk. However, larger dose and longer duration of thrombolysis were associated with increased bleeding risk.
Author List
Lee K, Istl A, Dubois L, DeRose G, Forbes TL, Wiseman D, Mujoomdar A, Kribs S, Power AHAuthor
Alexandra C. Istl MD, MPH Assistant Professor in the Surgery department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Arterial Occlusive DiseasesBiomarkers
Catheterization, Peripheral
Down-Regulation
Female
Fibrinogen
Fibrinolytic Agents
Hemorrhage
Humans
Infusions, Intra-Arterial
Infusions, Intravenous
Male
Punctures
Retrospective Studies
Risk Assessment
Risk Factors
Thrombolytic Therapy
Thrombosis
Tissue Plasminogen Activator
Treatment Outcome
Venous Thrombosis
